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Quantitative coronary and vascular angiography (QCA resp., QVA) remains the current gold standard for evaluation of restenosis.
Late loss as one of the most commonly accepted parameters to highlight eﬃcacy of the various devices has shown high correlation
toclinical parameters but,surprisingly,has noimpact on the evaluation of the remaining amount of restenostictissue. The current
clinical practice leads to unrealistic late loss calculations. Smaller late loss diﬀerences are usually not greater than the inherited
resolution limits of QCA, which is especially the case in small diﬀerences between the various stents in the drug-eluting stent era.
Late loss include additional systematic and random errors, due to the fact that measurements were taken at two diﬀerent time
points including the inherited resolution and calibration limits of QCA on two occasions. Due to the limited value of late loss in
discriminating the small diﬀerences between the one and other DES, late lumen area loss and clearly deﬁned calculation algorithms
(e.g., MLD-relocation) should be used in future DES studies also to fulﬁll the more stringent regulatory requirements.
1.Text
Endovascular therapy is a rapidly evolving ﬁeld for the
treatment of patients with peripheral arterial occlusive
disease (PAOD) or coronary artery disease (CAD), and
a magnitude of studies on technical improvements and
innovativedevelopmentshavebeenpublishedduring thelast
15 to 20 years. Studies assessing endovascular therapy of
peripheral or coronary arteries are tending to hover however
on uniformly deﬁned clinical and QCA-derived endpoints,
which became clinical practice on the basis of positive cor-
relations to clinical parameters over the last years. Although
these QCA-derived parameters were predominantly used to
reﬂect on the neointimal process and to predict restenosis,
their values were never evaluated or validated independently.
Unfortunately, in order to provide a comparison with
the already published studies, most of the subsequently
conducted studies used exactly the same QCA-derived study
endpoints. Moreover, because the guideline-relevant studies
are frequently based on exactly these QCA-derived study
endpoints, not only the outcomes of the studies but also
the guidelines themselves could therefore be biased by the
limitations of these surrogate parameters described in this
paper.
In this paper we highlight the algorithm and limitations
of late loss as one of the most frequently used QCA-derived
surrogatestudyendpointinthedescriptionofrestenosisafter
interventional lesion treatment and propose other already
available QCA-derived parameters as standardized and well
deﬁned study endpoint criteria for future restenosis studies
presumably based on independently evaluated study end-
point standards formulated by a corresponding consensus
committee.2 International Journal of Vascular Medicine
2. QCA QuantitativeCoronaryAnalysis
Because intra-arterial angiography remains the current gold
standard for the depiction of lesions in peripheral arter-
ies, quantitative coronary/vascular angiography (QCA) has
become a trusted tool to evaluate the restenotic process and
the relative eﬃcacy of percutaneous endovascular interven-
tions [1]. In order to avoid bias by the interventionist or
analysts, validated automatic edge detection became the gold
standard in QCA [2–4].
Angiographic parameters derived from QCA such as late
loss are common endpoints in stent trials [5–10] although
Semeraro and coworkers showed that the location of QCA-
based MLD failed to correlate with the location of IVUS-
based MLD and the correlation of late loss to “predict” IVUS
parameters of restenosis was just moderate [11].
3.QCA-BasedEstimationof MLD,Diameter
Stenosis (% DS),andLateLoss
Measurements of absolute minimum diameters are inde-
pendent of variations in reference diameter and the extent
of reduction in minimum diameter between the immediate
postangioplastyandfollow-upangiogramsdeﬁnestheextent
o fv e s s e lw a l lh y p e r p l a s i a .
Oneofthemostcommonlyusedangiographicendpoints
is late luminal loss, which is the diﬀerence between post-
procedure and follow-up minimal luminal diameter (MLD).
It is of utmost importance that late loss does not take
the absolute vessel dimensions anatomical or present after
the procedure into account (e.g., acute gain), but only the
lumen loss during the follow-up period after the procedure.
During the evaluation of late loss values, it is therefore
mandatory to always look at the MLD values after the ﬁnal
procedure. If a stent has not been implanted adequately
(which is probably a fact in almost 35% of the cases) the
remaining MLD (e.g., acute gain) remains lower compared
to an adequately implanted stent. The late loss calculation
however will be lower in cases where the stent was not
implanted adequately and where the MLD was lower after
the implantation procedure (Figure 1).
In addition, late loss does not take the amount of
restenostic tissue into account but exclusively describes the
smallest diameter inside the treated segment.
Nevertheless a curvilinear relationship between late loss
and the risk of having a target lesion revascularization (TLR)
could have been shown in the TAXUS trial [12, 13]a n da
positive correlation between late loss to binary angiographic
restenosis in the SIRIUS study [14].
Thereafter, late loss was used as a gold standard surrogate
clinical parameter in predicting restenosis and repeated re-
vascularisation [15, 16].
4. Late Loss Differences AreSmaller than
the QCA-Resolution Limits
Late loss is a bidimensional parameter deﬁned as the diﬀer-
ence between two focal MLD measurements (postprocedural
and at followup). As measurements are made at diﬀerent
time points, they are exposed to the inherent 0.2mm
resolution limit of QCA (which barely correspond to the
facet of one pixel). In addition, the calibration factor for each
MLD measurement is calculated using a diﬀerent guiding
catheter as the reference for each time point. All these factors
create systematic and random errors and may explain the
poor accuracy and precision of QCA analysis.
I nt h ed r u g - e l u t i n gs t e n te r a ,a b s o l u t el a t el o s sv a l u e s
became far smaller than values in the bare metal stent era.
Thus, comparing late loss can be relatively reliable when
comparing bare metal to drug-eluting stents due to the
expected large diﬀerence between the devices. Its value can
become trivial in trials comparing diﬀerent types of drug-
eluting stents. Indeed, little late loss diﬀerences detected
after deployment of diﬀerent drug-eluting stents can still be
signiﬁcant (due to the lower power needed by continuous
endpoints to ﬁnd statistical signiﬁcance), but their real
angiographic and clinical implication can be negligible.
When the diﬀerences between devices are small (in the order
of 0.1–0.4mm), doubts about the consistency of late loss as a
surrogate for the restenotic process will increase. Moreover,
if the resolution of QCA is approximately 0.2mm (e.g.,
around one pixel), late loss, as derived by two diﬀerent QCA
measurements(afterprocedureandatfollowup),canbeeven
more aﬀected by these resolution limits [17].
5. MLD andLateLoss Algorithms AreNeither
Uniform Nor Clearly Deﬁned
Althoughlatelossisclearlybeenestimatedonthebasisofthe
MLDvalues(afterprocedure;atfollowup),latelossdoestake
into account the location and amount of restenostic tissue
withintheanalysisregionandthereforemaynotbeuniform.
(1) The measurement of a very low MLD due to a spot
restenosis (e.g., in case of a nonadequately implanted
stent)ascomparedtotheintermediate-reducedMLD
in a uniformly diﬀuse but not high-degree in-stent
restenosis (reﬂecting a great amount of intimal
hyperplasia) does not help to distinguish which
device is associated with less intimal hyperplasia
(Figure 2).
Therefore, the estimation of late loss is independent
of the location, length, amount (volume), burden,
and distribution of the restenostic tissue and the
M L Di nc a s eo fe c c e n t r i cv e s s e la p p e a r a n c em a yb e
underestimated by a single monoplane QCA analysis.
(2) The measured MLD (in-segment) is not character-
ized according to its visual and clinical appearance:
the remaining target-lesion tissue (in-segment) due
to inadequate stent placement is measured as a
nontargetlesiontissuefromanewatheromatouswall
irregularity (in-segment) (Figure 1). Therefore, late
loss is calculated regardless of the respective axial
location of the MLD along the segments of a stent
betweenpostproceduralandfollow-upQCAanalysis.International Journal of Vascular Medicine 3
(a)
(b)
Baseline
After inadequate 
stent placement
After adequate
stent placement MLD (in-segment): 2.8 mm
MLD (in-segment): 2.8 mm
Figure 1: Inappropriate MLD description with similar MLD’s (in-segment): (a) in-segment MLD (red area) arising from nontarget lesion
tissue in a case after adequate stent placement (purple area) (b) in-segment MLD from in-target-lesion tissue in a case of inappropriate stent
landing zone.
Baseline
Stent
edge
Stent MLD (pp) Stent MLD (pp)
Case 1: stent adequately implanted,
diﬀuse in-stent restenosis
Case 2: stent not adequately implanted,
focal in-stent restenosis
 After procedure
Followup
LL = MLD(pp) − MLD(fu) = 1.8 mm LL = MLD(pp) − MLD(fu) = 9 mm
MLD (fu) MLD (fu)
Figure 2: Late loss without association to the true extent of neointimal hyperplasia. Case 2 has a signiﬁcant higher late loss, due to inade-
quately implanted stent (purple) at distal stent-edge (red) than case 1, although signiﬁcant more diﬀuse neointimal hyperplasia is present in
case 1.
(3) Late loss is a surrogate parameter for restenosis,
althoughthelatelossalgorhythmdoesnotnecessarily
allow its estimation at the site of postprocedural
MLD but also elsewhere along the stent [18, 19].
This means, that if stenosis remains somewhere
within the treated area or stent (e.g., due to high
restrictive areas in the lesion) and restenosis arises
in a diﬀerent area of the stent or stented-segment,
late loss is calculated signiﬁcantly lower as compared
with an algorithm calculating late loss exactly at
the corresponding place following the procedure.
This phenomenon is described as angiographic
MLD relocation, which occurs frequently and rep-
resents an important technical limitation aﬀecting
the value of late loss. MLD relocation has the
potential to impact adequate calculation of late loss
and thus the analysis and interpretation of stent
trial results. This commonly occurs in cases where
some atherosclerotic tissue remains in the proximal
stented segment and in-stent restenosis appears in
the distal stent-segment and the stented-segments
(proximal and distal) are irrationally calculated as
one today: the calculated late loss is outrageously low
(Figure 3).
(4) Although separate analysis of the QCA derived
parameters in the various stent-associated segments
became of central importance (i.e., brachytherapy,
ﬁrst drug-eluting stent trials), it later became com-
mon clinical practice to summarize the distal and
proximal stent-segment as one (stented-segment). It
became common practice to calculate the late loss of
the two opposite segments in one, regardless whether
there was MLD remained in the one segment and
restenotic tissue appeared in the other segment. This
lead to unpredictable errors and severe inaccuracies,
which do not reﬂect the real morphological situation
(Figure 4).4 International Journal of Vascular Medicine
Case-report: adequately inplanted stent, atheromatous
wall irregularities leading to MLD in prox. stent-edge,
diffuse in-stent restenosis distal stent + dist. stent-edge
Dist edge Prox edge In-stent
MLD-2 MLD-1
MLD-1 MLD fu
Baseline
After procedure
Followup
LL (in accordance to “deﬁnition”) = MLD(l)—MLD(fu)
LL (not in accordance to “deﬁnition”) = MLD(2)—MLD(fu)
Figure 3: Erroneous late loss algorithm. Although the late loss (= MLD-2−MLD-fu) would reﬂect the enormous neointimal hyperplasia at
the distal stent edge correctly (right red area), the erroneous algorithm/deﬁnition of late loss (in-segment) dictates to include the MLD from
the opposite stent edge (MLD-1) (left red area) into the equation, leading to an inaccurate lower late loss (not reﬂecting the true amount of
neointimal hyperplasia).
Followup
Baseline
 After procedure
Case 1: stent implanted, no rest-stenosis
diﬀuse in-stent restenosis distal
Case 2: stent implanted, rest-stenosis prox
diﬀuse in-stent restenosis distal
LL (with “MLD-relocation”) = MLD(2)—MLD(fu)
LL (without “MLD-relocation”) = MLD(l)—MLD(fu)
MLD 1 MLD 2
MLD(fu) MLD(fu)
Figure 4: In both cases, a diﬀuse in-stent restenosis is present. Although the amount of neointimal hyperplasia is exactly the same, the late
loss is signiﬁcantly lower in case 2 due to the remaining MLD-2 after procedure (e.g., restrictive stenosis or nonadequately deployed stent).
The red arrow indicates the distance of the MLD relocation from MLD-2 to MLD-fu.
6.Late Lumen Area Loss Effectively
Discriminatesthe Low Differences and
Resolution Limits betweenDES or DEB
With the use of the following QCA-derived parameters the
small diﬀerences between two DES or DEB in head-to-head
or noninferiority trials can clearly be diﬀerentiated. They
oﬀer exact information about the true amount and pattern
of the restenostic tissue after interventional treatment:
(1) lesionarea(inmm2;Figure 5,yellowarea;)andlumen
area deﬁned as area around the lesion area in a clearly
deﬁned vessel segment (in-stent; in-segment);International Journal of Vascular Medicine 5
Free-hand: 16.18 mm
Free-hand: 0.44 mm
Free-hand: 7.57 mm
Figure 5: A typical example of a QCA analysis (Medis QAngio,
Medis, The Netherlands) of a right coronary artery. Lumen area (in
mm2) is deﬁned as the area around the lesion area (yellow area) in a
clearly deﬁned vessel segment (in-stent; in-segment) (green lines).
(2) late lumen area loss (in mm2)d e ﬁ n e da s :late lumen
area loss = lumen area (after the ﬁnal procedure)-
lumen area (at followup);
(3) MLD relocation values >3( 5 ) m ma n dc o n s e c u t i v e
assessments of late lumen diameter loss calculated
on basis of MLD relocation should always be docu-
mented as such;
(4) the late lumen area loss and late lumen diameter loss
should always be assessed in the proximal and distal
segment separately.
7. Discussion
Although reducing the restenostic process is the central
rationale of the majority of coronary devices (i.e., drug-
eluting stents or balloons), late loss—as the most frequently
used surrogate parameter to highlight eﬃcacy of the various
devices surprisingly has no impact on the description of the
amount of restenostic tissue and its pattern and distribution.
The consistency of smaller late loss diﬀerences is inef-
fectual and not greater than the inherited resolution limits
of QCA which can become clinically evident in DES head-
to-head or noninferiority studies since late loss values
and diﬀerences in these studies became far less signiﬁcant
between the various stents. In addition, late loss includes
systematic and random errors, due to the fact that MLD
is measured at two diﬀerent time points, including the
inherited resolution and calibration limits of QCA on two
occasions.
While using this parameter interventionists must take
into account that late loss is calculated regardless of the
respectiveaxiallocationoftheMLDalongthecorresponding
segments leading to MLD-relocation not only in-stent but
also in-segment. This will frequently represent unrealistic
late loss calculations. Although these disadvantages may not
have an impact on the outcome in the majority of studies
(because of being present in the treatment—as well as in
the control arm), it is of major interest in smaller studies,
or in case of trials with unbalanced or heterogeneous study
groups.
In order to eliminate the major disadvantages of the
current late loss algorhythm described above, “area” should
be used in the late loss algorhythm instead of “diameter”
(MLA instead of MLD) leading to the Late lumen area
loss (LLAL), which has the potential to discriminate the
small diﬀerences between two DES or DEB in head-to-head
or non inferiority trials and oﬀer exact information about
the true amount and pattern of the restenostic tissue after
interventional treatment.
In addition, greater values of MLD relocation and its
consequences on late lumen diameter loss should always be
documented as such and the late lumen area loss and late
lumendiameterlossshouldalwaysbeassessedintheproximal
and distal segment separately.
In summary, the invention of late loss area loss (LLAL)
as a modiﬁcation of the well-established and accepted QCA-
derived surrogate parameter (LLL) eliminates the major
disadvantages of LLL and is an appropriate and reproducible
study endpoint for the evaluation of current and future
interventional techniques.
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